What is KPV?

Compound Spotlight

KPV is three amino acids long. That makes it one of the smallest molecules in this catalog, and the reason it is interesting: it appears to retain the anti-inflammatory activity of a much larger hormone while discarding the rest of what that hormone does.

Where it comes from

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide derived from proopiomelanocortin. It is best known for stimulating melanin production, but it also has well-documented anti-inflammatory properties, acting broadly across immune cell types.

Researchers working to separate those two activities found that the C-terminal tripeptide — residues 11 through 13, Lys-Pro-Val — retained much of the anti-inflammatory effect on its own. KPV is that fragment. The practical appeal is obvious: the anti-inflammatory activity without the pigmentation activity, in a molecule small enough to be cheap to synthesize and unusually stable.

The melanocortin-independent puzzle

The intuitive assumption would be that KPV works through the same melanocortin receptors as its parent hormone, just more selectively. The evidence points elsewhere.

KPV has demonstrated anti-inflammatory effects in systems where melanocortin receptors are absent or blocked, which argues that at least part of its activity does not require them. The prevailing interpretation is that KPV acts intracellularly rather than through cell-surface receptor signaling — it enters the cell and interferes with inflammatory signaling directly.

This is a meaningful distinction. A compound acting through a defined surface receptor has a clear pharmacological handle; one acting intracellularly through pathway interference is harder to characterize, harder to dose-relate, and harder to make selective. It also means KPV should not be assumed to behave like other melanocortin compounds such as PT-141 or the melanotans, despite the shared parentage.

NF-kB and why it is the target of interest

NF-kB is a transcription factor that functions as the central switch for inflammatory gene expression. In a resting cell it is held inactive in the cytoplasm by inhibitory IkB proteins. Inflammatory signals trigger IkB degradation, freeing NF-kB to enter the nucleus and drive transcription of cytokines, chemokines, and adhesion molecules.

KPV has been reported to interfere with this cascade, reducing NF-kB nuclear translocation and downstream pro-inflammatory cytokine production. Because NF-kB sits upstream of many inflammatory outputs at once, a compound acting there produces broad effects rather than blocking a single cytokine — which is both the appeal and the reason selectivity questions matter.

The PepT1 transporter detail

One of the more elegant findings in the KPV literature concerns how it gets into cells. KPV appears to be taken up via PepT1, a di- and tripeptide transporter. PepT1 is expressed at low levels in healthy colon but is upregulated in inflamed intestinal tissue.

The implication is a degree of self-targeting: uptake is greater precisely where inflammation is present. Work by Dalmasso, Merlin and colleagues explored this in colitis models, including nanoparticle delivery approaches designed to exploit it. Whether this translates beyond rodent models is unestablished, but as a mechanism it is genuinely clever rather than marketing gloss.

What the evidence supports

The KPV literature is preclinical. The strongest findings come from cell culture work and rodent models of colitis — typically DSS- or TNBS-induced — where KPV administration reduced inflammatory markers and histological damage scores. There is additional work in dermatological and mucosal inflammation models.

There are no human clinical trials. The tripeptide’s small size and stability make it an attractive candidate for development, and the mechanistic story is coherent, but the gap between rodent colitis models and human inflammatory disease is wide and has swallowed many compounds with equally coherent rationales. The honest position is that KPV has a plausible, partially characterized mechanism supported by animal data, and nothing more than that yet.

Frequently asked questions

Does KPV cause skin darkening like alpha-MSH?

No. Pigmentation effects depend on melanocortin receptor signaling driven by other regions of the alpha-MSH molecule. KPV lacks those regions and appears to act largely independently of melanocortin receptors.

Is KPV related to PT-141 or the melanotans?

Only by shared origin. Those compounds are melanocortin receptor agonists; KPV is an alpha-MSH fragment that appears to work through a different, largely intracellular mechanism. They should not be expected to behave alike.

Why does its small size matter?

Three amino acids means greater stability against enzymatic degradation than longer peptides, simple and inexpensive synthesis, and eligibility for transport through di-/tripeptide transporters like PepT1 that larger peptides cannot use.

How do I know what is actually in the vial?

Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.

References

• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.
• Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324–331.
• Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides. Endocr Rev. 2008;29(5):581–602.

View the KPV product listing →

Read our KLOW Blend breakdown →

Look up your lot Certificate of Analysis →

For laboratory and research use only. Not for human consumption. KPV has no human clinical trial data and is not approved by any regulatory authority. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.

Related research compounds

Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:

• KPV

For laboratory research use only. Not for human consumption.